Pemetrexed, a potent inhibitor of thymidylate synthase (TS) and other folate-dependent enzymes involved in purine and pyrimidine synthesis, has been approved as the first-line, second-line, and maintenance treatment for patients with non-squamous NSCLC [5, 6]. This evidence concerns the gene TYMS and non-small cell lung carcinoma.